Lawyer At Girard Sharp Llp
CurrentAs a named partner at Girard Sharp LLP, Dena currently serves as co-lead counsel in the In re JUUL Labs Inc. multidistrict litigation, In re Xyrem Antitrust Litigation, and In re California Gasoline Spot Market Antitrust Litigation. She is co-lead counsel for a certified class of end-payers in the In re Restasis Antitrust Litigation, and a member of the End-Payer Steering Committee in In re Generic Pharmaceuticals Pricing Antitrust Litigation, a massive case alleging that the world’s largest makers of generic drugs conspired to raise prices and prevent price competition for years. Dena is also privileged to represent clients of a fertility center whose eggs and embryos were compromised by a freezer tank malfunction. In June 2021, Dena and her team tried the first In re Pacific Fertility Center Litigation case in federal court in San Francisco, and won a groundbreaking $15 million jury verdict for the loss of four families’ eggs and embryos. As co-lead counsel in In re Lidoderm Antitrust Litigation, a “pay-for delay” antitrust case that settled for $104.75 million on the eve of trial, Dena worked with her team to win class certification, defeat summary judgment, and obtain the largest recovery for a class of end-payers in similar federal litigation in more than a decade. She has also played a key role in a variety of other high-profile cases, including work on behalf of the direct purchasers in the In re Capacitors Antitrust Litigation, and representing investors in litigation arising from Lehman Brothers’ bankruptcy and in matters involving Ponzi schemes and accounting fraud.
